Lambert B - Search Results

1

Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma.

Lambert B, De Ridder L, De Vos F, Slegers G, de Gelder V, Van de Wiele C, Thierens H. Lambert B, et al. Can J Physiol Pharmacol. 2006 Oct;84(10):1021-8. doi: 10.1139/y06-055. Can J Physiol Pharmacol. 2006. PMID: 17218968

2

Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.

Lambert B, Van de Wiele C. Lambert B, et al. Eur J Nucl Med Mol Imaging. 2005 Aug;32(8):980-9. doi: 10.1007/s00259-005-1859-z. Eur J Nucl Med Mol Imaging. 2005. PMID: 16032439 Review.

3

Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma.

Lambert B, De Ridder L, Slegers G, De Gelder V, Dierckx RA, Thierens H. Lambert B, et al. Can J Physiol Pharmacol. 2004 Feb;82(2):146-52. doi: 10.1139/y04-008. Can J Physiol Pharmacol. 2004. PMID: 15052296

4

Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.

De Ruyck K, Lambert B, Bacher K, Gemmel F, De Vos F, Vral A, de Ridder L, Dierckx RA, Thierens H. De Ruyck K, et al. Among authors: lambert b. J Nucl Med. 2004 Apr;45(4):612-8. J Nucl Med. 2004. PMID: 15073257 Free article. Clinical Trial.

5

188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.

Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, Dierckx RA, Van de Wiele C, Thierens H, De Vos F. Lambert B, et al. J Nucl Med. 2005 Jan;46(1):60-6. J Nucl Med. 2005. PMID: 15632035 Free article. Clinical Trial.

6

188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis.

Lambert B, Bacher K, De Keukeleire K, Smeets P, Colle I, Jeong JM, Thierens H, Troisi R, De Vos F, Van de Wiele C. Lambert B, et al. J Nucl Med. 2005 Aug;46(8):1326-32. J Nucl Med. 2005. PMID: 16085590 Free article. Clinical Trial.

7

(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.

Lambert B, Bacher K, Defreyne L, Van Vlierberghe H, Jeong JM, Wang RF, van Meerbeeck J, Smeets P, Troisi R, Thierens H, De Vos F, Van de Wiele C. Lambert B, et al. Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):344-52. doi: 10.1007/s00259-005-1954-1. Epub 2005 Dec 7. Eur J Nucl Med Mol Imaging. 2006. PMID: 16333675 Clinical Trial.

8

In vitro 2-deoxy-2-[18F]fluoro-D-glucose uptake: practical considerations.

Mertens K, Mees G, Lambert B, Van de Wiele C, Goethals I. Mertens K, et al. Among authors: lambert b. Cancer Biother Radiopharm. 2012 Apr;27(3):183-8. doi: 10.1089/cbr.2011.1125. Epub 2012 Feb 28. Cancer Biother Radiopharm. 2012. PMID: 22372557 Free article.

9

Renal toxicity after radionuclide therapy.

Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA, Otte A. Lambert B, et al. Radiat Res. 2004 May;161(5):607-11. doi: 10.1667/rr3105. Radiat Res. 2004. PMID: 15161361 Review.

10

Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome.

Lambert B, Praet M, Vanlangenhove P, Troisi R, de Hemptinne B, Gemmel F, Van Vlierberghe H, Van de Wiele C. Lambert B, et al. Cancer Biother Radiopharm. 2005 Apr;20(2):209-14. doi: 10.1089/cbr.2005.20.209. Cancer Biother Radiopharm. 2005. PMID: 15869457

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

848 results

Search Page

Filters